Best analyst reports for Disney, Amgen and Booking.com


Monday, November 15, 2021

Zacks Research Daily features the best research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (SAY), Amgen Inc. (AMGN) and Booking Holdings Inc. (BKNG). These research reports were handpicked from over 70 reports released today by our team of analysts.

You can see all today’s research reports here >>>

Actions of Disney outperformed Zacks’ media conglomerate industry over the past year (+ 10.3% vs. -6.3%). The Zacks analyst believes that Disney’s ever-expanding international footprint and strong content portfolio has driven the growth rate of Disney + users.

Disney + net additions are expected to be higher in the second half of fiscal 2022 compared to the first half. Upcoming movies including The king’s man should help the outlook of the segment. Disney, however, expects to incur high costs in FY2022 due to spending due to new projects such as Star Wars: Galaxy’s Edge, Avengers Campus, and the Epcot expansion.

(You can read the full Disney research report here >>>)

Amgen stocks have lost -6% during the year-to-date period compared to a loss of -13.7% for Zacks’ biomedical and genetics industry. Several of the drugs marketed by AMGN have recently faced rising prices. Growing competition for its traditional products is another headwind.

The Zacks analyst, however, believes key drugs like Prolia, Repatha, Xgeva and biosimilars have boosted sales. Amgen is rapidly advancing its strong pipeline of early and late stage assets. Several Phase III readings are scheduled for 2022. The launch of Lumakras, a leading treatment for lung cancer, holds great promise even though its label extension studies are progressing rapidly.

(You can read the full research report on Amgen here >>>)

Actions of Reserve assets gained + 10.3% in the last six months compared to a loss of -7.9% for Zacks’ internet commerce industry. Zacks analyst believes that BKNG continues to benefit from an impressive growth trend in the online travel booking market, strength in international markets as well as growth opportunities in the domestic market.

Another major tailwind is a substantial improvement in its booking trends following the removal of travel restrictions. Booking Holdings enjoyed solid momentum in Europe in the third quarter. Another positive element is the strong growth of agencies, traders and advertising companies. Steadily increasing advertising costs, fierce competition in the market and numerous disputes, however, weighed on margins.

(You can read the full research report on Booking Holdings here >>>)

Other noteworthy reports we feature today include General Motors Co. (DG), Moody’s Corp. (AGC) and BCE Inc. (AEC).

Marc Vickery
Editor-in-chief

Note: Sheraz Mian heads the equity research department at Zacks and is a renowned expert on aggregate earnings. He is frequently cited in print and electronic media and publishes the weekly Income trends and Income overview reports. If you would like to receive an email notification every time Sheraz publishes a new article, please click here >>>

5 actions in the process of doubling

Each was selected by a Zacks expert as the # 1 favorite stock to earn + 100% or more in 2021. Previous recommendations climbed + 143.0%, + 175.9%, + 498.3% and + 673.0%.

Most of the stock in this report is flying under Wall Street’s radar, which provides a great opportunity to get into the ground floor.

Today, discover these 5 potential circuits >>

Click to get this free report

Moody’s Corporation (MCO): free share analysis report

Amgen Inc. (AMGN): Free Stock Analysis Report

BCE, Inc. (BCE): Free Stock Analysis Report

The Walt Disney Company (DIS): Free Stock Analysis Report

General Motors Company (GM): Free Inventory Analysis Report

Booking Holdings Inc. (BKNG): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks investment research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.